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Background/aim: Dipeptidyl peptidase-4 (DPP4) inhibitors, a class of oral antidiabetic drugs, have been shown to be protective on the
vascular system because of their antiinflammatory, antiatherosclerotic, and vasodilatory effects. ß2-adrenoceptors (ß2-ARs) mediate the
vasorelaxation in the aorta. However, ß3-adrenoceptor-mediated relaxation has not been studied in diabetic aorta yet. Thus, we aimed to
study the effect of sitagliptin treatment on ß2- and ß3-adrenoceptor-mediated relaxations in the diabetic rat aorta.

Materials and methods: Eight-week old Sprague Dawley rats were divided into three groups: control, diabetic, sitagliptin treated
diabetic. Diabetes was induced by injection of streptozotocin (35 or 40 mg/kg, intraperitoneally). After 10 weeks of diabetes, some
of the diabetic rats were treated with sitagliptin (orally, 10mg/kg/day). ß2- and ß3-AR-mediated relaxation responses were evaluated
by using isoprenaline and CL 316,243, respectively. ß3-AR-mediated relaxation experiments were repeated in presence of L-NAME.
Western blotting and immunohistochemistry were performed to determine the abundance of ß3-adrenoceptor and endothelial nitric
oxide synthase (eNOS).
Results: The isoprenaline-mediated relaxation response was impaired in the diabetic group and sitagliptin treatment did not improve
it. There was no significant change in CL316,243 mediated-relaxation or protein expression of ß3-ARs among the groups. However, the
ratio of phosphorylated eNOS/NOS protein was increased markedly in the sitagliptin treated group, which points the stimulating effect
of this drug towards the eNOS pathway.
Conclusion: Our results indicate that sitagliptin treatment does not alter ß-AR-mediated relaxation in streptozotocin-diabetic rat aorta;
however, it significantly stimulates the eNOS pathway. Future studies are needed to clarify the relationship between the eNOS pathway
and DPP-4 inhibition.
Key words: ß-adrenoceptors, aorta, streptozotocin induced diabetes, sitagliptin, endothelial nitric oxide synthase

1. Introduction
Chronic diabetes has detrimental effects on the
vasculature [1,2]. Antidiabetic drugs with additional
vascular protective features have been paid attention in
this regard. Dipeptidyl peptidase-4 (DPP4) inhibitors have
been shown to exert antiinflammatory, antiatherosclerotic,
and vascular protective effects [3,4]. On the other hand,
there is an ongoing debate on whether these benefits are
independent of metabolic control (euglycemia). Vellecco
et al. [5] have demonstrated that linagliptin, a DPP-4
inhibitor, treatment improved relaxation response in
nonobese diabetic mice despite the lack of metabolic
control. Furthermore, Shah et al. [6] have reported
that alogliptin-mediated relaxation was not related to
glucagon-like peptide (GLP-1) but rather to nitric oxide
(NO) and endothelium-derived hyperpolarizing factor

(EDHF) in the aorta of C57BL/6 mice. On the contrary,
sitagliptin has been effective in improving the glucose
metabolism and endothelial dysfunction in high fat fedlow dose streptozotocin (STZ) injected rat aorta [7].
Hence, this finding was attributed to activation of AMPK
signaling pathway through elevated GLP-1 levels. On the
other hand, the direct effect of sitagliptin has been tested
in the thoracic aorta of New Zealand white rabbits [8].
The drug caused vasorelaxation in the phenylephrine
precontracted aorta. This effect has been suggested to be
mediated through voltage dependent K+ channels and
protein kinase A (PKA).
Relaxation in thoracic aorta is mediated mainly
through ß2-adrenoceptors (ß2-ARs). However, ß3-ARs, the
third subtype of adrenoceptors, have been suggested to
contribute to vasodilatation through nitric oxide synthase
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(NOS) and cyclic guanosine monophosphate (cGMP) [9].
Flacco et al. [10] have confirmed this finding as they have
shown the presence of ß3-AR and its vasodilator effect in
the rat aorta. On the other hand, Brahmadevara et al. [11]
have indicated that CL 316,243, a selective ß3-adrenoceptor
agonist, failed to induce relaxation in the rat aorta. The
reason behind these conflicting results remains unclear.
It is well known that relaxation response in the diabetic
aorta is impaired [12–14]. The blunted vasorelaxation
response in diabetes has been referred to either
endothelium dysfunction [13,15] or decreased ß-AR
mediated responsiveness [14,16]. However, the possible
alteration in ß3-AR-mediated relaxation due to diabetes
has not been investigated yet.
Thus, the present study has two aims; first, to investigate
the effect of sitagliptin on ß2- and ß3-AR-mediated
relaxation in STZ diabetic rat aorta and second, to clarify
whether this effect is dependent on metabolic control.
2. Materials and methods
2.1. Chemicals
Sitagliptin (JANUVIA, 100 mg, Merck Sharp & Dohme,
USA); streptozotocin, phenylephrine, isoprenaline,
CL 316,243, L-NAME (Sigma, USA); anti-ß3 antibody
(ab59685, Abcam, USA), anti-eNOS antibody (9572S, Cell
Signaling Technology, USA), anti-phosphorylated eNOS
(ser1177) antibody (9571S, Cell Signaling Technology,
USA), anti-α-tubulin antibody (ab4074, Abcam, USA),
antichicken antibody (29710, AnaSpec, USA), antirabbit
antibody (7074, Cell Signaling Technology, USA).
2.2. Animals
The study protocol was approved by the animal welfare
committee of Ankara University (permit: 2015-15-172)
and was in line with the National Institutes of Health
(NIH) guidelines for care and ese of laboratory animals.
Eight-week old male Sprague Dawley rats (200–250g) were
purchased from Bilkent University and Gazi University,
then housed under a 12 h light/night cycle in the animal
facility of Pharmacy Faculty of Ankara University. The rats
were exposed to food and water Ad Libitum.
2.3. Induction of diabetes and sitagliptin treatment
Rats were divided randomly into three groups; control
(C), diabetic (D) and sitagliptin treated diabetic group (S).
Diabetes was induced by injection of streptozotocin (35
or 40 mg/kg, intraperitoneally). Their blood glucose was
measured with a glucometer after 72 h of injection and rats
with blood glucose levels lower than 300 mg/dL received
second or, if necessary, the third dose of STZ (40 or 45 mg/
kg, respectively). After a 10-week diabetes period, S group
was treated with sitagliptin (10mg/kg/day, once a day) for
4 weeks. Sitagliptin doses ranging from 5 mg/kg/day to
50 mg/kg/day have been used in the experimental studies

[17–20]. We compared the effectiveness of 10 mg/kg/day
[7,19, 21] versus 30 mg/kg/day [7], the most common
used doses, on the vasodilatation. Since we did not find a
significant difference between the doses, we decided to use
the lower dose. For this purpose, Januvia tablets (128.5 mg
sitagliptin phosphate monohydrate equivalent to 100 mg
sitagliptin) were crushed and suspended in distilled water.
The suspension was administered to the rats orally. The C
and D groups received distilled water.
2.4. Isolated organ bath experiments
Thoracic aorta was isolated under ether anesthesia and kept
in Krebs solution (120 mM NaCl; 4.8 mM KCl; 1.25 mM
CaCl2.2H2O; 1.25 mM MgSO4.7H2O; 1.2 mM KH2PO4; 25
mM NaHCO3, and 10 mM glucose monohydrate). Fat and
connective tissue was cleaned carefully to avoid damaging
the integrity of the endothelium, and the aorta was cut into
4–5 mm long rings. The rings were placed in the organ
bath filled with Krebs solution to record isometric force.
Two platinum hooks were inserted through the lumen
of the aortic rings. One of the hooks was attached to the
organ bath chamber. The second hook was attached to an
isometric force displacement transducer (MAY, GTA0303,
Commat Ltd, Turkey). The transducer was connected to
data acquisition system (MAY, MP30B-CE, 310B2428,
Commat Ltd., Turkey). The temperature was set at 37 0C
and baths were oxygenated continuously (O2 95% CO2 +
5%). The resting tension was set to 2 g. Aorta strips were
incubated for 1 h with washing out every 15 min.
After the incubation period, rings were challenged with 10
µM phenylephrine. Once the contraction response reached
to plateau, the integrity of the endothelium was checked
with 10 μM acetylcholine. The ß2-AR-mediated relaxation
response was determined with isoprenaline (1 nM–10
μM) in the rings precontracted with a submaximal dose of
phenylephrine. ß3-AR-mediated relaxation response was
evaluated with ß3-AR selective agonist CL 316,243 (0.01
nM–1 μM) and this response was repeated in presence of
L-NAME (100 μM).
2.5. Western blotting
Thoracic aorta strips were powdered with liquid nitrogen
and homogenized with RIPA solution. After sonication,
they were agitated for 2 h at 4 0C, and centrifuged at 12,000
rpm for 30 min at 4 0C. Protein concentration was measured
using the bicinchoninic acid (BCA) assay. Protein samples
(60 μg) were loaded onto polyacrylamide gel (TGX Fast
Cast, 7.5%) and transferred to polyvinylidene difluoride
(PVDF) membranes. Membranes were blocked with 5%
bovine serum albumin (BSA) and incubated with primary
antibodies overnight at 4 0C; ß3-adrenoceptor (1/250),
eNOS (1/500), phosphorylated eNOS (peNOS) (1/1000,
serine-threonine 1177). After washing with tris buffered
saline tween 20 (TBST), buffer membranes were incubated
with secondary antibodies for 2 h at 4 0C; antichicken,
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(1/3000), antirabbit, (1/2000). Protein bands were detected
with enhanced chemiluminescence assay and exposed
to film. Quantification of protein bands was done using
Image J (NIH, USA). The expression level was normalized
to the housekeeping gene, α-tubulin (1/10000).
2.6. Immunohistochemistry
Aorta tissue samples were fixed in 10% paraformaldehyde
solution at least 24 h. Aorta tissues were embedded
in paraffin wax, then the tissues were cut into 4–5 µm
sections after fixation. To demonstrate the ß3-AR and
eNOS protein in the aorta, immunohistochemical analysis
was carried out by following instructions of indirect
immunoperoxidase streptavidin/biotin kit protocol.
Accordingly, specimens were treated with eNOS and ß3-AR
antibodies by the streptavidin-biotin immunoperoxidase
technique. The color reaction was obtained by using
3-amino-9-ethylcarbazole (AEC) chromogen and Mayer’s
hematoxylin counterstain.
2.7. Statistical analysis
The results were expressed as mean ± standard error
(SEM). The statistical significance was tested by one way

ANOVA. The difference between the groups was tested
using the Bonferroni’s multiple comparison test. A value
of P < 0.05 was considered significant.
3. Results
3.1. General characteristics of the rats
At the end of the 14-week diabetes period, blood glucose
level was higher in diabetic group as expected and
sitagliptin treatment did not attenuate it (C: 102.6 ± 5.96
mg/dL; D: 480.1 ± 19.57 mg/dL; S: 465.1 ± 22.49; P <
0.0001) (Figure 1A). In addition, diabetic rats lost weight
significantly and sitagliptin treatment did not normalize
it (C: 381 ± 8.47 g; D: 315.3 ± 8.55 g; S: 316,4 ± 6.28; P <
0.0001) (Figure 1B).
3.2. ß2- and ß3-AR-mediated relaxation responses in
thoracic aorta
The nonselective ß-AR agonist, isoprenaline, induced
dose-dependent relaxations in all groups. The responses
were markedly lower in the diabetic group and not
improved by sitagliptin treatment (Figure 2A). The
maximum relaxation response was similar in both diabetic

Figure 1. General characteristics of rats. A) blood glucose levels. B) body weights. ***P < 0.001; compared
to C group. C, control group; D, diabetic group; S, sitagliptin treated diabetic group.

Figure 2. Isoprenaline induced relaxation response. A) cumulative dose response curve. B) maximum response at 10 μM isoprenaline.
**P < 0.01; compared to C group. C, control group; D, diabetic group; S, sitagliptin treated diabetic group.
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and treated groups (C: 66.73 ± 2.01%; D: 47.99 ± 1.90%; S:
47.62 ± 1.99%; P = 0.0013) (Figure 2B).
The selective ß3-AR agonist, CL 316,243, induced
dose-dependent relaxations in all groups as well (Figure
3A). The maximum response at 10 μM CL 316,243 was not
statistically significant among the groups (C: 8.77 ± 0.46%;
D: 10.19 ± 0.49%; S: 9.67 ± 0.59%; P = 0.6649) (Figure 3B).
The pD2 values, which are the marker for the affinity of the
drug to the receptor, of isoprenaline, and CL 316,243 are
shown in the Table. The relaxation response of CL 316,243
was abolished in the presence of L-NAME (100 μM, 30
min), an eNOS inhibitor (Figure 3C).
3.3. Protein expression levels of ß3-AR, eNOS and peNOS
There was no significant change in protein expression
of ß3-AR between the groups despite a slight increase in
diabetic and sitagliptin-treated diabetic groups (C: 100.00
± 11.12; D: 110.7 ± 17.9; S: 116.6 ± 8.79; P = 0.6448)
(Figure 4A). There was a slight but insignificant increase in
eNOS protein expression in the diabetic groups (C: 100.00
± 10.84; D: 132.0 ± 18.56; S: 110.8 ± 28.69; P = 0.6291)
(Figure 4B). On the other hand, eNOS phosphorylation
was greater in sitagliptin treated diabetic group (C: 100.00
± 38.66; D: 53,71±34,49; S: 235.1 ± 50.25; P = 0.028)
(Figure 4C). The ratio of phosphorylated eNOS (peNOS)
to eNOS was augmented in the sitagliptin treated group
(C: 100.00 ± 35.33; D: 72.40 ± 22.91; S: 288.4 ± 58.65; P =
0.0209) (Figure 4D).
3.4. Immunohistochemical parameters
The eNOS immunohistochemical staining observed in the
diabetic group was higher compared to the control group.
It was reduced in sitagliptin treated group (C: 8.03 ± 0.39%;
D: 9.36 ± 0.23%; S: 8.16 ± 0.40%; P = 0.0319) (Figure 5A).
The ß3-AR immunohistochemical staining was observed
in the endothelial layer and there was no significant difference between the groups (C: 0.78 ± 0.03%; D: 0.85 ±
0.04%; S: 0.84 ± 0.03%; P = 0.3852) (Figure 5B).

Table. The pD2 (logEC50) values of isoprenaline and CL 316,243.
pD2
ISO (%)
CL (%)

C
7.07 ± 0.10
(n = 8)
9.71 ± 0.24
(n = 14)

D
7.24 ± 0.13**
(n = 10)
8.98 ± 0.18
(n=16)

S
6.58 ± 0.11**
(n = 10)
9.04 ± 0.22
(n = 10)

4. Discussion
In the present study, we demonstrated that a 4-week
sitagliptin treatment did not improve suppressed ß2adrenoceptor-mediated relaxation response in diabetic
rat aorta. Furthermore, we found that ß3-adrenoceptormediated relaxation response was not altered in STZdiabetic or sitagliptin treated STZ-diabetic rat thoracic
aorta.
We did not observe a beneficial effect of sitagliptin on
isoprenaline-induced vasorelaxation. However, previous
studies have reported that DPP-4 inhibitors ameliorated
relaxation response in diabetic aorta [5,7,21]. Tang et al.
[7] have shown that acetylcholine-induced-relaxation is
improved after sitagliptin treatment in high fat fed-low
dose STZ injected rats. Furthermore, Wang et al. [21] have
confirmed that sitagliptin positively affects acetylcholineinduced relaxation in Zucker Diabetic Fatty (ZDF) rats.
However, it should be kept in mind, that both studies
have focused on the effects of sitagliptin on endotheliumdependent vasorelaxation. However, different from both
studies mentioned above, we investigated the effect of
sitagliptin on ß2-AR mediated vasodilatation. The effect
of DPP-4 inhibitors on isoprenaline-induced relaxation
response was tested with linagliptin by Vellecco et al. [5].
Linagliptin significantly corrected vasorelaxation in type
I diabetic Nonobese Diabetic (NOD) mice. In addition,
Vellecco et al. [5] have underlined that the effect of
linagliptin on vasodilatation is stronger than sitagliptin.

Figure 3. CL 316.243 mediated relaxation response. A) cumulative dose response curve. B) maximum response at 10 μM CL 316,243.
C) cumulative dose response curve in the presence of L-NAME. C, control group; D, diabetic group; S, sitagliptin treated diabetic group.
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Figure 4. Protein expression levels. A) % relative intensity of ß3-ARs normalized to α-tubulin B) % relative intensity of eNOS normalized
to α-tubulin C) % relative intensity of peNOS normalized to α-tubulin D) the ratio of peNOS to eNOS. #P < 0.05; compared to D
group. C, control group; D, diabetic group; S, sitagliptin treated diabetic group.

One possible parameter that affects vasodilator activity
of sitagliptin may be the metabolic control. Unlike us, Tang
et al. [7] and Wang et al. [21] were able to attenuate blood
glucose levels with sitagliptin treatment. However, Vellecco
et al. [5] have indicated that they observed improved
relaxation response despite the lack of metabolic control.
Thus, the beneficial vascular effect of linagliptin has been
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suggested as independent of glucose control and attributed
to its interaction with GLP-1 and GLP-1 receptor. Actually,
there is an ongoing debate on whether the positive effects
of DPP-4 inhibitors are related to metabolic control or if
it is GLP-1 dependent [22]. It is well known that ß2-AR
mediated-vasodilatation is blunted in diabetic rat aorta
[21]. Similarly, isoprenaline induced-relaxation was

MÜDERRİSOĞLU et al. / Turk J Med Sci

Figure 5. The (AEC) chromogen and Mayer’s hematoxylin counterstain. A) eNOS positive staining area (magnification, 100). B) ß3-AR
positive staining area. The arrow indicates the endotelium limited staining (magnification, 100). *P < 0.05; compared to C group. C,
control group; D, diabetic group; S, sitagliptin treated diabetic group.
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impaired in our study and the 4-week sitagliptin treatment
did not normalize it. Contrary to our findings, Vellecco
et al. [5] have reported the improving effect of linagliptin
in NOD mice. Regarding the discrepancy between our
findings and those of Vellecco et al. [5], it remains unclear
whether it arises from animal species, DPP-4 inhibitor
used, or other specific factors in the signaling pathway. It
is hard to make further comments as we were unable to
investigate the molecular alterations in the ß2-AR-mediated
relaxation pathway. Future studies focusing on the effects
of sitagliptin on cAMP, PKA or other components in the
relavant pathways could help us interpret our findings.
We also studied ß3-AR mediated vasorelaxation in
diabetic rat aorta. We have found that CL 316,243, a
selective ß3-AR agonist, caused dose-dependent relaxation
in rat aorta. We have also demonstrated that ß3-ARs were
localized in the endothelium. Our findings are in line with
the previous studies on ß3-AR-mediated-vasorelaxation
and the localization of the receptor [9,10,23]. We proposed
that the response may be different in diabetic aorta since
ß3-AR-mediated cardiac responses have been found to be
changed in diabetes [24,25]. Furthermore, the expression
of this subtype is upregulated in cardiac pathologies such
as diabetes or heart failure [24–29]. However, unlike to
the situation in the heart, we found that neither relaxation
response nor protein expression of ß3-AR was altered due
to diabetes. Moreover, sitagliptin treatment had no impact
on these parameters.
Since ß3-AR-mediated vasodilation has been suggested
to be NOS dependent [9,10], we further determined the
protein expression and activation of eNOS. The protein
expression of eNOS was slightly increased in diabetic
and sitagliptin treated group, however, this increase was
not statistically significant. On the other hand, the ratio
of phosphorylated eNOS to eNOS, a marker of eNOS
activation, was significantly increased in sitagliptin treated
group. The effect of incretin mimetics on eNOS has been
investigated in previous studies. Ding and Zhang [30] have
reported that incubation with GLP-1 caused activation
and phosphorylation of eNOS in human umbilical vein
endothelial cells (HUVEC) after 5 min. Protein expression
of eNOS was augmented after 48 h. Thus, our findings
demonstrating no significant change in protein expression
of eNOS, despite an increased ratio of phosphorylated
eNOS to eNOS in sitagliptin-treated rats might be related to
the duration of treatment. In addition, both exenatide and
GLP-1(9-36) increased the expression, phosphorylation,
and activation of eNOS [30]. On the other hand, this effect
was partially inhibited when DPP-4 inhibitor sitagliptin
or GLP-1 receptor antagonist exendin (9-36) was added.
Thus, the effect of GLP-1 on eNOS has been suggested to
be related both through GLP-1 receptor and GLP-1(9-36).
Supporting this idea, Hu et al. [31] have indicated that the
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effect of DPP-4 inhibitors on human vascular endothelial
cells has both GLP-1-dependent and -independent
components. Considering the findings of Ding and Zhang
[30], our results on protein expression of eNOS could be
attributed to the inhibited conversion of GLP-1 to GLP1(9-36) by sitagliptin. However, this hypothesis could not
explain the augmented eNOS phosphorylation in sitagliptin
treated group. On the other hand, our results are parallel
to the findings of Matsubara et al. [3]. They demonstrated
that eNOS protein expression was preserved, whereas
eNOS phosphorylation was markedly increased in desfluoro-sitagliptin treated apoE deficient high-fat-fed mice.
In this study, desfluorositagliptin caused phosphorylation
of eNOS via the cAMP/PKA pathway by increasing GLP-1
activity in HUVEC. This phosphorylation further decreased
endothelial inflammation, ageing and apoptosis [3].
The main findings of our study could be summarized
as follows; first, sitagliptin treatment, at least at a dose that
does not establish a metabolic control, was ineffective in
improving ß2-AR-mediated vasorelaxation in STZ-diabetic
rats; second, ß3-AR-mediated relaxation was not changed
in diabetic and sitagliptin treated diabetic groups; third,
eNOS phosphorylation was augmented in sitagliptin
treated group. It remains unclear whether the lack of
improved relaxation response by sitagliptin results from the
insufficient metabolic control or another cause. Moreover,
the significance of the stimulating effect of sitagliptin on
the eNOS pathway should be further determined. Future
studies with higher doses and longer duration of sitagliptin
treatment in comparison to other DPP-4 inhibitors could
help to clarify these points.
A limitation of the current study was the lack of a
sitagliptin treated control group. A control group with
sitagliptin treatment could have been helpful to explain
whether the augmented eNOS pathway in sitagliptin
treated-diabetic group results from the drug or diabetes
itself. However, we were unable to include this group in our
study. Another limitation was the lack of a sitagliptin treated
diabetic group with metabolic control. In that case, we would
have elucidated whether the negative results of the treatment
arise from the lack of the metabolic control. Another missing
part of the study is the mechanism underlying impaired ß2AR-mediated relaxation response and augmented eNOS
activation. Further studies on the effect of sitagliptin on
signaling pathways could help to clarify it.
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